Efficacy and Safety of Ruxolitinib Cream in Patients With Mild to Moderate Hidradenitis Suppurativa: Results From a Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study

Published: 10 October 2025| Version 1 | DOI: 10.17632/2crdgphf82.1
Contributor:
M. Celeste Ferreira-Cornwell

Description

Supplemental data for an article published in the Journal of the American Academy of Dermatology

Files

Categories

Ruxolitinib, Hidradenitis Suppurativa, Janus Kinase

Licence